Prefilled Syringes Market Summary

• The Prefilled Syringes market was valued at USD 12,490.79 million in 2024 and expected to reach USD 27,993.35 million by 2032.
• Prefilled Syringes Market is expected to grow at a CAGR of 10.73% during the forecast period from 2025 to 2032.

Prefilled Syringes Market Insight and Trends

• The global prefilled syringes market is growing due to the rise in chronic diseases, increased use of biologics and biosimilars, and the adoption of self-administration.
• The staked needle system category in the prefilled syringes market is estimated to dominate the prefilled syringes market with a market share of 68.37% in 2024.
• Key Prefilled Syringes Companies are BD, NIPRO Pharma, Taisei Kako Co.,Ltd, TERUMO PHARMACEUTICAL SOLUTIONS., SCHOTT AG, Gerresheimer AG, West Pharmaceutical Services, Inc., Dali Medical Devices, Stevanato Group, Credence MedSystems, Inc., Baxter, MAEDA INDUSTRY Co., Ltd., MedXL Inc, IRISYS, LLC, Sandoz International GmbH, Pfizer Inc., Vetter, Weigao Group, Fresenius Kabi, Catalent Inc and others.
• North America is estimated to hold the largest share of 34% in the global prefilled syringes market in 2024, growing at a CAGR of 11.02% during the forecast period from 2025 to 2032.

Prefilled Syringes Market Size and Forecasts

• 2024 Market Size: USD 12,490.79 million
• 2030 Projected Market Size: USD 27,993.35 million
• Growth Rate (2025-2032): 10.73% CAGR
• Largest Market: North AmericaAsia-Pacific
• Fastest Growing Market: Asia-Pacific
• Market Structure: Moderately Consolidated

Rising prevalence of chronic diseases & long-term conditions

Growing global incidence of chronic diseases - such as diabetes, rheumatoid arthritis, autoimmune diseases, cardiovascular conditions - increases demand for regular injections. Prefilled syringes offer a convenient, accurate, ready-to-use format for chronic therapies.

Increasing use of biologics, biosimilars, and injectable therapies

As more biologic drugs (and biosimilars) enter the market, many require parenteral/injectable delivery. Prefilled syringes - because of sterility, dose accuracy, and stability - become the preferred delivery medium for these therapies.

Shift toward self-administration and home-healthcare delivery models

Patient preference for self-injection (at home or outside hospital settings), especially for chronic conditions, fuels demand for syringe formats that are easy to use, safe, and don’t require medical professional support. Prefilled syringes satisfy those needs.

Safety, convenience, and reduction of medication errors

Prefilled syringes come pre-measured, pre-sterilized - reducing risk of dosing errors, contamination, overfill waste, and needle-stick injuries. These advantages are attractive to both healthcare providers and patients.

Expansion of vaccination/immunization programs & growing demand for injectable vaccines / drugs

Prefilled syringes are widely used for vaccines and immunizations - which require mass, rapid, safe, accurate administration - making them standard in large-scale immunization and prophylactic programs.

Technological advancements in syringe design & materials

Innovations - e.g. dual-chamber syringes (for lyophilized drugs), safety-engineered syringes, improved glass or polymer materials, better compatibility for biologics - enhance usability, drug stability, and open the door to more drug types.

Growth of healthcare infrastructure & increased access in emerging markets

As emerging economies expand their healthcare systems, there is increased demand for modern, safe, and efficient drug delivery devices. Prefilled syringes benefit from wider adoption in these regions.

Regulatory and safety trends favoring prefilled devices

Increasing emphasis on patient safety, standardization (to prevent contamination, dosage errors, needle-stick injuries), and regulatory support for safety-engineered devices encourage adoption of prefilled syringes over traditional vial-and-syringe systems.

Pharmaceutical companies’ and CMOs’ increasing production capacity and investment

Manufacturers scaling up dedicated prefilled-syringe production lines (or captive facilities), to meet demand for biologics and injectable therapies, supports greater supply and accelerates adoption.

Need for improved efficiency in hospitals and clinical settings

Prefilled syringes reduce preparation time, reduce waste, lower contamination risks, and simplify workflows in hospitals and clinics - making them attractive for institutional procurement and use.

Prefilled Syringes Market by Product Type (Staked Needle System, Luer Cone System, and Luer Lock System), Material (Glass and Plastic), Type (With Needle and Without Needle), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of chronic diseases, increase impact of biologics and biosimilar on prefilled syringes, increase adoption of self-administration across the globe.

The prefilled syringes market was valued at USD 12,490.79 million in 2024, growing at a CAGR of 10.73% during the forecast period from 2025 to 2032 to reach USD 27,993.35 million by 2032. The global prefilled syringes market is growing due to the rise in chronic diseases, increased use of biologics and biosimilars, and the adoption of self-administration. Chronic conditions like diabetes and rheumatoid arthritis require ongoing injectable treatments, and prefilled syringes offer patients a safe, convenient way to manage their care. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the shift towards self-administration at home enhances convenience and boosts the overall demand for prefilled syringes. Collectively, these factors foster a robust growth trajectory for the prefilled syringes market during the forecast period from 2025 to 2032.

What are the latest Prefilled Syringes Market Dynamics and Trends?

According to the recent data provided by the World Heart Organization (2023), about 528 million people globally were living with osteoarthritis.

Additionally, according to the recent data provided by the Institute for Health Metrics and Evaluation (2023), by 2050, nearly one billion people are projected to have osteoarthritis, with the most common areas affected being the knees and hips. Specifically, knee osteoarthritis is expected to increase by 74.9%, osteoarthritis of the hand by 48.6%, osteoarthritis of the hip by 78.6%, and osteoarthritis in other areas, such as the elbow and shoulder, by 95.1%. 

Patients with osteoarthritis often need hyaluronic acid or corticosteroid injections for pain relief and joint mobility. Prefilled syringes provide a convenient and sterile method for administering these treatments in clinical and home settings, thus boosting the global prefilled syringe market. For example, Synvisc-One® manufactured by Genzyme Corporation, which is a subsidiary of Sanofi is a prefilled syringe that helps lubricate and cushion the knee joint, offering relief from osteoarthritis pain for up to six months.

Additionally, as per recent data from the World Health Organization (2023), it was reported that over 1.8 million people worldwide were affected by multiple sclerosis. Multiple sclerosis impacted various functions, including cognitive, emotional, motor, sensory, and visual abilities, as the immune system mistakenly attacked the brain and spinal cord. Prefilled syringes were crucial for managing the condition, as they simplified dosing, reduced medication errors, and enhanced patient adherence to treatment regimens by offering a ready-to-use, accurate, and user-friendly delivery system. For instance, AVONEX is a once-weekly treatment for relapsing multiple sclerosis, provided as a 30 mcg intramuscular prefilled self-syringe.

Moreover, Biologics, including monoclonal antibodies, growth factors, and vaccines, are crucial for treating chronic conditions like cancer and autoimmune diseases. Administered via injection, prefilled syringes offer a convenient and accurate delivery method. Additionally, the rise of biosimilar generic versions of biologics has further propelled the demand for prefilled syringes, providing a more affordable treatment option.

For instance, in July 2024, Sandoz Group AG, a global leader in generic and biosimilar medicines, announced that the U.S. Food and Drug Administration (FDA) approved its biosimilar Pyzchiva®* (ustekinumab-ttwe) in 45 mg/0.5 mL and 90 mg/mL pre-filled syringes for subcutaneous injection, as well as a 130 mg/26 mL (5 mg/mL) single-dose vial for intravenous infusion.

Thus, the factors mentioned above are expected to boost the overall prefilled syringes market across the globe during the forecast period from 2025 to 2032.

However, increasing product recalls and failures due to safety issues and the availability of alternative products may hinder the future of prefilled syringes market across the globe during the forecasted period.

Prefilled Syringes Market Segment Analysis

Prefilled Syringes Market by Product Type (Staked Needle System, Luer Cone System, and Luer Lock System), Material (Glass and Plastic), Type (With Needle and Without Needle), Distribution Channel (Hospital & Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

The staked needle system category in the prefilled syringes market is estimated to dominate the prefilled syringes market with a market share of 68.37% in 2024. The adoption of staked needle systems is significantly boosting the overall prefilled syringes market by addressing key challenges in drug delivery and enhancing the usability, safety, and efficiency of injectable therapies. A staked needle system integrates the needle directly into the syringe barrel, eliminating the need for additional assembly, such as attaching a separate needle. This design simplifies the injection process, reduces preparation time, and minimizes the risk of needle-related complications, such as detachment or improper attachment, making it highly preferred in both clinical and self-administration settings.

One of the major drivers of the staked needle system's impact is its contribution to patient safety. The fixed-needle design reduces the risk of needle-stick injuries, which is a critical concern for healthcare professionals, especially in high-pressure environments like hospitals and emergency care. Additionally, the reduced dead space in staked needle systems ensures precise dosing and minimizes medication waste, which is particularly advantageous for high-cost biologics, vaccines, and specialty drugs. This attribute makes staked needle systems an ideal choice for administering small-volume, high-potency medications, aligning with the growing demand for precision medicine. The integration of staked needle systems into advanced prefilled syringes, such as autoinjectors and pen injectors, further boosts their appeal in the rapidly growing self-injection device market.

Prefilled Syringes companies are increasingly adopting staked needle systems for their prefilled syringes due to their compatibility with a wide range of drugs, including biologics and biosimilars, which are gaining traction globally. The design ensures the sterility and integrity of the drug product, reducing the likelihood of contamination or degradation. Furthermore, staked needle systems are well-suited for high-speed, automated manufacturing processes, enabling efficient large-scale production while maintaining consistent quality, which aligns with the rising demand for prefilled syringes worldwide.

Thus, the factors mentioned above are expected to boost the segment thereby boosting the overall market of prefilled syringes across the globe.

Prefilled Syringes Regional Analysis

North America is expected to dominate the overall prefilled syringes market

Among all regions, North America is estimated to hold the largest share of 34% in the global prefilled syringes market in 2024, growing at a CAGR of 11.02% during the forecast period from 2025 to 2032. This can be attributed to the rising prevalence of various chronic disorders such as diabetes, autoimmune diseases, and others. The use of biologics and biosimilars for complex conditions like cancer and autoimmune diseases has further driven demand for user-friendly injection systems. Additionally, the increase in strategic activities among the key prefilled syringes companies are further boosting the overall prefilled syringes market across the region.

According to data provided by the Centers for Disease Control and Prevention (CDC) in 2023, it was estimated that around 53.2 million people (21.2%), had been diagnosed with arthritis and rheumatoid arthritis in the United States, between 2019 to 2021.

Additionally, as per the data provided by the Centers for Disease Control and Prevention 2024, it was stated that around 38.4 million, accounting for 11.6% of the US population was suffering from diabetes, in 2021. Chronic diseases like diabetes and rheumatoid arthritis require continuous treatment over the long term. Patients need regular injections to manage their conditions, often for the rest of their lives. Prefilled syringes make these daily treatments easier, and more accurate, and allow easy self-administration of medications at home.

Furthermore, the well-established patient care system along with high awareness among patients and caregivers regarding different types of prefilled syringes is further expected to propel the United States prefilled syringes market growth.

Moreover, the increasing use of prefilled syringes highlights the rapid adoption of technologically advanced solutions, which is expected to drive prefilled syringes market growth. For instance, in March 2024, Mallinckrodt plc. announced that the U.S. FDA approved the Acthar® Gel (repository corticotropin injection) Single-Dose SelfJect™ Injector, a new delivery device for Acthar Gel for patients with chronic and acute inflammatory and autoimmune conditions. The SelfJect was designed to allow patients greater control over their medication administration.

Thus, the above-mentioned factors are expected to escalate the prefilled syringes market in the region.

Who are the major players in Prefilled Syringes?

The following are the leading companies in structural heart devices. These companies collectively hold the largest structural heart devices market share and dictate industry trends.

Prefilled Syringes Companies

Some of the key prefilled syringes companies and manufacturers operating in the market include BD, Nipro Corporation, Taisei Kako Co., Ltd., Terumo Corporation, SCHOTT Pharma AG & Co. KGaA, Gerresheimer AG, Johnson and Johnson Services, Inc., Dali Medical Devices, Stevanato Groupand, Credence MedSystems, Inc., Baxter, MAEDA INDUSTRY Co., Ltd., MedXL, Inc., Sanofi, Sandoz AG, Pfizer Inc., B. Braun Melsungen AG, Novartis AG, Fresenius SE & Co. KGaA, Cardinal Health, and others.

Recent Developmental Activities in the Prefilled Syringes Market

• In May 2025, Samsung Bioepis and Organon announced FDA designated HADLIMA™ (adalimumab-bwwd) autoinjectors and high-concentration prefilled syringe as interchangeable biosimilars to Humira®. Combined with prior approvals, HADLIMA is now interchangeable with all Humira® presentations.
• In March 2025, ANI Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) approval of Purified Cortrophin® Gel (repository corticotropin injection USP) in a prefilled syringe format.
• In March 2024, SCHOTT Pharma expanded in the U.S. with a new prefillable syringe manufacturing facility in Wilson, North Carolina with a $371 million investment.
• In May 2024, InvAscent, through India Life Sciences IV (ILSF IV), partnered with Morgan Stanley Private Equity Asia to invest INR 10,000 million in Maiva Pharma, recognized as India’s second-largest pure-play injectables Contract Development and Manufacturing Organization (CDMO). The funds raised were intended to enhance vial, lyophilization, and suspension capacity, as well as to introduce new manufacturing capabilities, including prefilled syringes, cartridges, and bags.

Key Takeaways From the Prefilled Syringes Market Report Study

• Market size analysis for current prefilled syringes market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key prefilled syringes companies dominating the prefilled syringes market.
• Various opportunities available for the other competitors in the prefilled syringes market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current prefilled syringes market scenario?
• Which are the regions and countries where prefilled syringes companies should have concentrated on opportunities for prefilled syringes market growth in the coming future?

Target Audience Who Can be Benefited From This Prefilled Syringes Market Report Study

• Prefilled syringes product providers
• Research organizations and consulting companies 
• Prefilled syringes-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in prefilled syringes 
• Various end-users who want to know more about the prefilled syringes market and the latest technological developments in the prefilled syringes market.